| Similar Articles |
|---|
 |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.   |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
The Motley Fool
December 15, 2008
Brian Orelli |
Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it? |
The Motley Fool
March 23, 2009
Brian Orelli |
Good News for Eli Lilly's Depression Drug Eli Lilly announces that the Food and Drug Administration has expanded the label of Symbyax to treat patients with treatment-resistant depression, meaning they haven't been helped by at least two other drugs. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
September 28, 2007
Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
March 28, 2008
Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
BusinessWeek
September 5, 2005 |
Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine. |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
Chemistry World
September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. |
The Motley Fool
August 17, 2007
Brian Orelli |
FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions. |
The Motley Fool
June 9, 2011
Brian Orelli |
It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation. |
The Motley Fool
September 7, 2007
Brian Orelli |
Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug. |
The Motley Fool
November 18, 2009
Brian Orelli |
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. |
The Motley Fool
May 18, 2009
Brian Orelli |
Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
February 23, 2010
Brian Orelli |
Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Bio-IT World
June 17, 2004 |
Minority Report With Iressa, the AstraZeneca drug approved by the FDA last year, there is a small group, maybe 10 to 20 percent of lung cancer patients, who get an almost miraculous response. Mutations may explain patient responses to the drug. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
August 3, 2011
Brian Orelli |
Ignore Pfizer's Financials for Now It's the pipeline that matters. |
The Motley Fool
May 30, 2006
Rich Duprey |
NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders? |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
April 20, 2010
Jim Mueller |
Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors. |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still. |
BusinessWeek
January 30, 2006
Catherine Arnst |
Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk. |
The Motley Fool
December 14, 2006
Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
January 11, 2011
Brian Orelli |
A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
July 9, 2009
Brian Orelli |
Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable. |
The Motley Fool
March 30, 2011
Brian Orelli |
Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
March 28, 2008
Brian Orelli |
The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug. |
The Motley Fool
February 4, 2010
Brian Orelli |
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. |
BusinessWeek
May 20, 2009
Maria Bartiromo |
Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
